L'analyste Trung Huynh ne modifie pas sa recommandation. UBS demeure neutre sur le dossier. L'objectif de cours est toujours fixé à 31 USD.

Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

A total of 438 confirmed and probable cases of meningococcal disease were reported in 2023, the most US cases reported since ...

Hawaii is the only US state that hasn't reported H5N1 avian flu in birds or animals. The state hasn't reported any recent ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Health agencies, counties and state officials have been resisting efforts to provide booster jabs to Americans this fall.

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...